Trials / Completed
CompletedNCT04312347
Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels
Tamoxifen Dose Adjustment on ER+ Breast Cancer Patients Based on Genomic and Metabolite Concentrations Analysis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Nalagenetics Pte Ltd · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations based on the CYP2D6 genotypes and endoxifen levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tamoxifen dose adjustment | Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day. |
Timeline
- Start date
- 2019-09-06
- Primary completion
- 2021-05-01
- Completion
- 2021-06-30
- First posted
- 2020-03-18
- Last updated
- 2021-08-05
Locations
1 site across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT04312347. Inclusion in this directory is not an endorsement.